Lv51
920 积分 2022-07-17 加入
An updated patent review of MALT1 inhibitors (2021-present)
3小时前
待确认
Treatment for dry age-related macular degeneration: where we stand in 2024
14天前
已完结
Targeting both death and paracaspase domains of MALT1 with antisense oligonucleotides overcomes resistance to immune-checkpoint inhibitors
24天前
已完结
MALT1 Inhibitors and Degraders: Strategies for NF-κB-Driven Malignancies
25天前
已完结
A pH-sensitive liposome formulation of a peptidomimetic-Dox conjugate for targeting HER2 + cancer
1个月前
已完结
225Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy
1个月前
已完结
Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019
2个月前
已完结
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study
2个月前
已完结
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
2个月前
已完结
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study
2个月前
已完结
皖公网安备34019202002308
